Israel - hebreo - Ministry of Health

teva pharmaceutical indust.ltd - venlafaxine as hydrochloride 75 mg - capsules - venlafaxine - for the treatment of depression. maintenance of recurrent depression. generalized anxiety disorder (gad) - short term and long-term. social anxiety disorder (sad).

Israel - hebreo - Ministry of Health

teva pharmaceutical indust.ltd - venlafaxine as hydrochloride 150 mg - capsules - venlafaxine - for the treatment of depression. maintenance of recurrent depression. generalized anxiety disorder (gad) - short term and long-term. social anxiety disorder (sad).

Israel - hebreo - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 30 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated.

Israel - hebreo - Ministry of Health

eli lilly israel ltd - duloxetine as hydrochloride - capsules - duloxetine as hydrochloride 60 mg - duloxetine - duloxetine - - cymbalta is indicated for the treatment of major depressive episodes. - cymbalta is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy. - cymbalta is indicated for the treatment of generalized anxiety disorder (gad).- cymbalta is indicated for the management of fibromyalgia.- cymbalta is indicated for the management of chronic muscoskeletal pain. this has been established is studies in patients with chronic low back pain and chronic pain due to osteoarthritis when other therapies have failed or are contra-indicated..

Israel - hebreo - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 30 mg - capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

Israel - hebreo - Ministry of Health

novartis pharma services ag - methylphenidate hydrochloride 20 mg - capsules - methylphenidate - attention deficit hyperactivity disorder (adhd).

Israel - hebreo - Ministry of Health

inovamed ltd - rivastigmine as hydrogen tartrate 1.5 mg - capsules - rivastigmine - symptomatic treatment of mild to moderately severe alzheimer's dementia.symptomatic treatment of mild to moderately severe dementia associated with parkinson's disease.

Israel - hebreo - Ministry of Health

cts ltd - metyrapone 250 mg - capsules - metyrapone - diagnostic test of secondary adrenocortical insufficiency, treatment of resistant edema associated with increased aldosterone secretion.

Israel - hebreo - Ministry of Health

taro international ltd - lansoprazole 15 mg - capsules - proton pump inhibitors - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome.treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.

Israel - hebreo - Ministry of Health

taro international ltd - lansoprazole 30 mg - capsules - proton pump inhibitors - for the treatment of duodenal ulcer, benign gastric ulcer, reflux oesophagitis and acid related disorders of the upper gastrointestinal tract. healing, long term treatment and maintenance therapy for patients with gastro oesophageal reflux disease (gord) or duodenal ulcer. prevention of relapse in patients with gord or duodenal ulcer. eradication of h. pylori from the upper gastrointestinal tract in patients with duodenal ulcer, gastritis or benign ulcer (in combination with appropriate antibiotics). short term treatment (up to four weeks) of heartburn and/or upper epigastric pain associated with acid-related dyspepsia. long-term management of pathological hypersecretory conditions including zollinger ellison syndrome. treatment and prophylaxis of nsaid- associated benign gastric ulcers, duodenal ulcers and relief of symptoms in patients requiring continued nsaid treatment.